The 11-beta-hydroxysteroid dehydrogenase type1 (11ßHSD1) is an NADP + -dependent oxido-reductase, usually reductase, of major glucocorticoids. The NAD + -dependent 11ßHSD2 is an oxidase that inactivates cortisol and corticosterone, conferring extrinsic specificity of the mineralocorticoid receptor for aldosterone. We reported that addition of a reducing agent to renal homogenates results in the monomerization of 11ßHSD2 dimers and a significant increase in NAD + -dependent corticosterone conversion. Estrogenic effects on expression, dimerization, and activity of the kidney 11ßHSD1 and 2 enzymes are described herein. Renal 11ßHSD1 mRNA and protein expression were decreased to very low levels by estradiol (E2) treatment of both intact and castrated male rats; testosterone had no effect. NADP + -dependent enzymatic activity of renal homogenates from E2-treated rats measured under non-reducing conditions was less than that of homogenates from intact animals. Addition of 10mM dithiothreitol to aliquots from these same homogenates abrogated the difference in NADP + -dependent activity between E2-treated and control rats. In contrast, 11ßHSD2 mRNA and protein expressions were significantly increased by E2-treatment. There was a marked increase in the number of juxtamedullary proximal tubules stained by the antibody against 11ßHSD2 after the administration of E2. Notwithstanding, neither the total corticosterone and 11-dehydrocorticosterone excreted in the urine, nor their ratio, differed between E2 or vehicle-treated rats. NAD + -dependent enzymatic activity in the absence or presence of a reducing agent demonstrated that the increase in 11ßHSD2 protein was not associated with an increase in in vitro activity unless the dimers were reduced to monomers.
INTRODUCTION
The glucocorticoids corticosterone and cortisol circulate at 100 to 1000 times the levels of aldosterone in plasma and have similar affinities for the mineralocorticoid receptor (MR) to that of aldosterone (3; 14) . Aldosterone binds the MR and modulates vectorial transport of sodium and water across epithelia in mineralocorticoid target tissues, such as the kidney and colon, where extrinsic specificity of the MR for aldosterone is provided by the enzyme 11ß-hydroxysteroid dehydrogenase type 2 (11ßHSD2) (7; 8) .
This enzyme converts corticosterone and cortisol to their inactive metabolites 11-dehydrocorticosterone and cortisone, respectively, before they can interact with the MR (7; 8) (2; 31). The 11 -18-hemiacetal of aldosterone prevents it from being a substrate for the 11ßHSD2.
Two 11ßHSD isozymes have been cloned and characterized. 11ßHSD1 is NADP + -dependent, has a high Km of 1-3 µM for corticosterone and cortisol, is bi-directional, though in vivo and in intact cells it is primarily a reductase. It does not colocalize with the MR in the kidney (19; 30; 32) . The 11ßHSD2 is NAD + dependent, acts only as a dehydrogenase, has a Km for corticosterone and cortisol low enough to be relevant to circulating levels of free glucocorticoids (4-14 nM) , and is colocalized with the MR in aldosterone target tissues (15; 31) . 11ßHSD2 has been cloned from kidney cDNA libraries of the human (2), sheep (1), rabbit (23) , mouse (6) , cow (29) and rat (42). In addition to classical aldosterone target cells, data from in situ hybridization studies indicate that 11ß-HSD2 mRNA is expressed in several other tissues, including the female rat reproductive system and CNS (26) (27) (28) .
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The direction of 11ßHSD1 activity, reduction or oxidation, in vitro is dependent upon substrate concentration, cofactor and type of preparation. Prior to the mid 1990's, when the existence of a second 11ßHSD was confirmed (2) , there was confusion about the bidirectionality of the 11ßHSD enzyme in different tissues under different experimental conditions. Significant 11ßHSD2 activity in the rat kidney was difficult to demonstrate until the recent report that the addition of the reducing agent dithiothreitol (DTT) to the incubation mixture of renal homogenates in the presence of NAD + resulted in significant conversion of tritiated corticosterone to tritiated 11-dehydrocorticosterone (11 Orchiectomies were done under isoflurane anesthesia delivered in oxygen with a veterinary anesthesia machine using standard aseptic surgical procedures through a midline skin incision in the scrotum. The tunicas vaginalis were obliterated to prevent intestinal herniation and entrapment. There were 10 male Sprague-Dawleys in each group for the urinary steroid excretion studies. Intact and castrated male rats received sc injections of control oil, 5 mg estradiol valerate, or 5 mg testosterone propionate.
Injections were given 2 days after surgery, before the animals were placed in metabolism cages without urine collection funnels. After 4 days of acclimatization to the metabolism cages, the rats received a second injection of estradiol valerate, testosterone or vehicle, Western blot for 11ßHSD2 and 11ßHSD1. Rat kidney microsomes were isolated by differential centrifugation as described before (21) . Microsomes were solubilized using
Laemmli buffer with or without 10 mM -mercaptoethanol (16) Measurements of urinary corticosterone and 11-dehydrocorticosterone. A 1 ml aliquot of urine mixed with 3 H-corticosterone (~3,000 dpm) was extracted with 25% dichloromethane in hexane, washed with water, evaporated under air, and reconstituted in ELISA buffer. An aliquot was used for measurement of recovery. ELISAs for corticosterone and 11-dehydrocorticosterone were performed using antibodies raised in sheep against corticosterone-and 11-dehydrocorticosterone-3-carboxymethoxylaminechicken serum albumin conjugates and methods developed by us as described (9; 20).
The anti-corticosterone antibody has a cross-reactivity of 0.83% with 11-dehydrocorticosterone, 2.7% with cortisol, 12.5% with deoxycorticosterone, 2.5% with progesterone, and 0.083% with 18-OH-deoxycorticosterone. The antibody against 11-dehydrocorticosterone has a cross-reactivity of 0.81% with corticosterone, <0.09% with cortisol, 0.75% with deoxycorticosterone, 0.11% with cortisone, and 0.1% with progesterone. Two consecutive 24 hour urine collections were pooled after an acclimatization period to achieve an average 24 hr excretion over 2 days.
Immunohistochemistry
The kidneys from perfused animals were fixed over night at room temperature in STF, embedded in paraffin, and cut in 6 µm slices. Immunocytochemistry was performed within 2 weeks of sectioning the tissue using an antibody we raised in sheep against a recombinant 11ßHSD2 enzyme (11) at a dilution of 1/2000, followed by anti-sheep affinity purified biotin labeled antibody, detected using a streptavidin-peroxidase system (Zymed Laboratories, S. San Francisco, CA) and DAB (Sigma, St. Louis, MO.), and counterstained with Gil hematoxylin.
Statistical analysis
Differences in the measured variables between control treated samples were evaluated by ANOVA, followed by a Bonferroni test, where appropriate, using a STATISTICA 6.0 (StatSoft) package. Results are expressed as the mean ± SEM.
RESULTS
Levels of male rat kidney 11ßHSD1 mRNA, measured by RPA ( fig.1 11ßHSD2 protein expression (n=2). The dimer/monomer ratio was 1.3 for control, which was not significantly different from the ratio for E2 treatment, 1.6. In a similar experiment in which microsomal protein was extracted with the reducing agent -mercaptoethanol, n=4, the optical density quantified directly, ± SEM, was 7.0 ± 1.3 au for control and 35.2 ± 5.2 for E2 treated rats; p=0.0018.
11ßHSD2 activity was very low for both treatment groups when the kidney microsomes were incubated in buffer alone and increased progressively when increasing concentrations of DTT were added to the incubation media ( Fig 5A) . While there was almost no NAD + -dependent activity when 20 g of kidney microsomes from control and estrogen treated rats were incubated in buffer without DTT, NAD + -dependent activity in all samples was increased in the presence of 1 mM and 10 mM of DTT. To better appreciate the difference in activity in the different treatment groups, kidney microsomal protein was decreased to 5 g in the incubation (Fig 5B) . Under these conditions, NAD + -dependent activity of kidneys from estradiol-treated rats was increased by 71% compared to control rats, 26.7±2.6 compared to 15.6±1.1 percent conversion of 3 H-corticosterone.
The 24 hour excretion of corticosterone, 11-dehydrocorticosterone or the ratio of corticosterone to 11-dehydrocorticosterone in the urine, a measurement of 11ßHSD activity in vivo, were not significantly altered by castration or treatment of male rats with estradiol ( fig. 6 ).
The pattern of expression of the 11ßHSD2 enzyme in the kidneys of control rats as assessed by immunohistochemistry was similar to that described by others (34) and consistent between animals of a given treatment group. In the present study, as in others (18), 11ßHSD1 mRNA and protein are decreased to almost undetectable levels in the kidneys of animals treated with estradiol.
However, in vitro NADP + -dependent activity decreased by less than 50% in incubations under non-reducing conditions but not when the incubations are performed with 10 mM DTT in the media. This is further evidence that NADP + -dependent 11ßHSD activity in the kidney may be mediated by an enzyme different from the 11ßHSD1 or 2, as previously suggested by us and others (12; 18) . Measurements of the 11ßHSD1 in microsomes are usually done by determining the enzymatic activity of the dehydrogenase reaction because the reductase activity is very unstable (19) . Even in liver microsomes the dehydrogenase reaction is easily measured, while the reductase has been difficult to measure. 11ßHSD1 acts exclusively as a reductase in intact hepatocytes in primary culture (13) . Incubation of the kidney microsomes in the presence of 500 nM corticosterone and NADP + makes it unlikely that the activity seen is due to a contribution of the 11ßHSD2 since the activity of this enzyme is very low in the absence of NAD + . In addition, a high level of substrate produces substrate inhibition of the 11ßHSD2 enzyme (21) .
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Estradiol treatment of both intact and castrated male rats resulted in a large increase in the mRNA and protein expression of the 11ßHSD2 enzyme. The demonstration by immunocytochemistry of a marked increase in 11ßHSD2 expression induced by estradiol in proximal tubules of the corticomedullary junction corroborates the results of western blot analysis. Despite this increase, when enzymatic activity was measured in the absence of a reducing agent, no significant activity in microsomes from either control or treated animals was seen, as previously reported (11) (Fig 5A) . Even in the presence of 10 mM DTT, which we have shown to optimize 11ßHSD2 activity in kidney homogenates (11) , estradiol treatment results in only a 73% increase in NAD + -dependent conversion of cortisol to 11-dehydrocorticosterone (Fig 5B) . It has been proposed that activity of the 11ßHSD2 may be regulated by the formation of inactive dimers that act as a latent form of the enzyme (4).
Castration of male rats and estradiol treatment produced no change in the urinary excretion pattern or amounts of corticosterone and 11-dehydrocorticosterone. The increase in 11ßHSD2 enzyme expression produced by estradiol treatment is not adequately represented by an increase in in vitro and in vivo enzymatic activity. Activity of 11ßHSD1 in microsomes was similar in estradiol-treated and control rats when optimal reducing amounts of DTT was added. Estradiol may promote the formation of dimers of both the 11ßHSD1 and 2 enzymes in an unknown manner. If regulated, dimerization or monomerization of the 11ßHSDs would serve as a mechanism for rapid modulation of enzymatic activity, thus MR and GR mediated events, at the cellular level.
Several inactivating mutations in the gene for 11ßHSD2 have been described in the syndrome of Apparent Mineralocorticoid Excess. Lack of 11ßHSD2 activity allows the E-00409-2002.R2 more abundant endogenous glucocorticoids access to the MR in mineralocorticoid target tissues, increasing both the ratio of cortisol to cortisone metabolites in plasma and urine and the half-life of cortisol and producing clinical signs of mineralocorticoid excess (22; 40) . Similar, though less severe, differences in cortisol metabolite excretion have been found in a subset of essential hypertensives compared to controls (38) . In a third of these patients the half-life of cortisol exceeded 2 SD of the mean, though no 11ßHSD2 gene mutation was found. This milder form of Apparent Mineralocorticoid Excess could be due to post-translational changes in the protein altering enzyme activity, perhaps by increased inactivation through dimer formation. Results of studies using cells transfected with the cDNA encoding the defective 11ßHSD2 of patients with Apparent Mineralocorticoid
Excess have been puzzling. There was small, but measurable 11ßHSD2 activity in the intact cells, but no activity in homogenates (39) . The mutations in these patients might not only produce enzymes that are less effective, but they may also promote the formation of inactive dimers which are more apparent when cells are homogenized.
Levels of 11ßHSD1 and 11ßHSD2 are independently regulated in the placenta and fetal tissues through out gestation (32) . The interconversion of cortisol and corticosterone differs in the mother, fetus and placenta at mid-term in baboons, as well as other mammals (37) . Estrogens, rather than adrenocorticoid substrate or product, were found to regulate this difference (24; 36) . 11ßHSD2 in the placenta maintains normal fetal blood glucocorticoid levels in the face of elevated maternal glucocorticoids early in the pregnancy and relatively high 11ßHSD2 levels in the fetal brain protect the developing brain throughout, when 11ßHSD2 in the placenta decreases significantly near term, E-00409-2002.R2 allowing maternal glucocorticoids, crucial for fetal lung maturation, to enter the fetal circulation (5; 25).
The data presented herein support the possibility that in addition to the genomic regulation of 11ßHSD enzyme expression by estrogens, increasing levels of estrogenic steroids exert a post-transcriptional regulation of 11ßHSD2. Estrogens increase near term. 11ßHSD2 dimerization in some organs, but not in others, in response to periparturient elevations of estrogens might be a mechanism to insure that glucocorticoids pass to the maturing fetal lungs without loss of 11ßHSD2 protection of MR where still needed, for example, in the kidney and brain.
In conclusion, both message and protein for the NADP + -dependent 11ßHSD1 was reduced to very low levels by estradiol in both intact and castrated male rats. However, enzymatic activity did not change, particularly when the reducing agent DTT was added to the incubation media. These data support the suggestion that another NADP + -dependent enzyme with 11ßHSD activity exists. There have been other reports of 11ßHSD activity that does not appear to be due to either 11ßHSD1 or 2, but as yet no other enzyme has been isolated or gene cloned (10; 12; 18) . Despite a large increase in message and protein measured by both western blot and immunocytochemistry for the 11ßHSD2 enzyme, in vivo activity, as measured by the ratio of urinary corticosterone to 11-dehydrocorticosterone ratio, did not change in estradiol-treated rats. We have previously reported that reducing agents separate inactive 11ßHSD dimers into active monomers. In this study NADP + -dependent enzyme activity in renal microsomes from estradiol-treated rats was lower than that of controls under non-reducing conditions, but was restored to the 
